Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer

被引:23
作者
Hellyer, Jessica A. [1 ]
White, Maya N. [1 ]
Gardner, Rebecca M. [2 ]
Cunanan, Kristen [2 ]
Padda, Sukhmani K. [1 ]
Das, Millie [1 ,3 ]
Ramchandran, Kavitha [1 ]
Neal, Joel W. [1 ]
Wakelee, Heather A. [1 ]
机构
[1] Stanford Univ, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA
[2] Stanford Sch Med, Quantitat Sci Unit, Stanford, CA 94305 USA
[3] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA
关键词
Gene interaction; Targeted therapy; NSCLC; Driver mutations; Osimertinib; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; GEFITINIB; SURVIVAL; ADENOCARCINOMA; SENSITIVITY; EXPRESSION;
D O I
10.1016/j.cllc.2021.09.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of co-mutations in the differential response to EGFR TKIs in L858R mutant versus exon 19 deletion lung cancer is unknown. We retrospectively evaluated the impact of co-mutations on outcomes with frontline EGFR TKI therapy in 137 patients. We found shorter time to treatment failure in the L858R cohort, and this difference was driven by the presence of co-mutations. Background: In most studies, patients with EGFR L858R mutant non-small cell lung cancer (NSCLC) have a shorter duration of response to EGFR tyrosine kinase inhibitor (TKI) therapy than do patients with EGFR exon 19 deletion NSCLC. The role that co-mutations play in this observation is unknown. Methods: We performed a single-institution retrospective analysis of patients with EGFR-mutant NSCLC (exon 19 deletion or L858R mutation) who received frontline EGFR TKI for metastatic disease between 2014 and 2019, and who had STAMP next-generation sequencing (NGS), a 130-gene platform. Time to treatment failure (TTF) and overall survival were calculated using Cox models adjusted for age, race, and brain metastases. Co-mutations in key tumor suppressor genes (TP53, RB1, KEAP1, CDKN2A, or CTNNB1) were identified and their effects on outcomes were evaluated. Analyses were stratified according to receipt of osimertinib versus nonosimertinib as frontline EGFR TKI. Results: Of 137 patients, 72 (57%) had EGFR exon 19 deletions and 65 (43%) had EGFR L858R mutations. Median TTF and OS on frontline TKI was shorter for the L858R cohort versus the exon 19 deletion cohort in univariate analysis. In adjusted models, this difference persisted for TTF but was no longer significant for OS. The difference in TTF in L858R mutant tumors was driven by the presence of co-mutations in key tumor suppressor genes. Conclusion: Patients with metastatic NSCLC with mutations in EGFR L858R had shorter TTF on frontline TKI compared to patients with EGFR exon 19 deletions. Co-mutations in tumor suppressor genes may play an important role in the differential response to TKI therapy.
引用
收藏
页码:264 / 272
页数:9
相关论文
共 37 条
[1]   Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research [J].
Austin, Peter C. .
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2009, 38 (06) :1228-1234
[2]   Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer [J].
Bhateja, Priyanka ;
Chiu, Michelle ;
Wildey, Gary ;
Lipka, Mary Beth ;
Fu, Pingfu ;
Yang, Michael Chiu Lee ;
Ardeshir-Larijani, Fatemeh ;
Sharma, Neelesh ;
Dowlati, Afshin .
CANCER MEDICINE, 2019, 8 (04) :1459-1466
[3]   Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers [J].
Blakely, Collin M. ;
Watkins, Thomas B. K. ;
Wu, Wei ;
Gini, Beatrice ;
Chabon, Jacob J. ;
McCoach, Caroline E. ;
McGranahan, Nicholas ;
Wilson, Gareth A. ;
Birkbak, Nicolai J. ;
Olivas, Victor R. ;
Rotow, Julia ;
Maynard, Ashley ;
Wang, Victoria ;
Gubens, Matthew A. ;
Banks, Kimberly C. ;
Lanman, Richard B. ;
Caulin, Aleah F. ;
St John, John ;
Cordero, Anibal R. ;
Giannikopoulos, Petros ;
Simmons, Andrew D. ;
Mack, Philip C. ;
Gandara, David R. ;
Husain, Hatim ;
Doebele, Robert C. ;
Riess, Jonathan W. ;
Diehn, Maximilian ;
Swanton, Charles ;
Bivona, Trever G. .
NATURE GENETICS, 2017, 49 (12) :1693-+
[4]   Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs [J].
Canale, Matteo ;
Petracci, Elisabetta ;
Delmonte, Angelo ;
Bronte, Giuseppe ;
Chiadini, Elisa ;
Ludovini, Vienna ;
Dubini, Alessandra ;
Papi, Maximilian ;
Baglivo, Sara ;
De Luigi, Nicoletta ;
Verlicchi, Alberto ;
Chiari, Rita ;
Landi, Lorenza ;
Metro, Giulio ;
Burgio, Marco Angelo ;
Crino, Lucio ;
Ulivi, Paola .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
[5]   Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib [J].
Carey, Kendall D. ;
Garton, Andrew J. ;
Romero, Maria S. ;
Kahler, Jennifer ;
Thomson, Stuart ;
Ross, Sarajane ;
Park, Frances ;
Haley, John D. ;
Gibson, Neil ;
Sliwkowski, Mark X. .
CANCER RESEARCH, 2006, 66 (16) :8163-8171
[6]  
Chen Z, 2018, INT J CLIN EXP PATHO, V11, P4644
[7]   ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies [J].
Chuang, Jody C. ;
Stehr, Henning ;
Liang, Ying ;
Das, Millie ;
Huang, Jane ;
Diehn, Maximilian ;
Wakelee, Heather A. ;
Neal, Joel W. .
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) :833-842
[8]   Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment [J].
Duan, Jianchun ;
Xu, JiaChen ;
Wang, Zhijie ;
Bai, Hua ;
Cheng, Ying ;
An, Tongtong ;
Gao, Hongjun ;
Wang, Kai ;
Zhou, Qing ;
Hu, Yanping ;
Song, Yong ;
Ding, Cuimin ;
Peng, Feng ;
Liang, Li ;
Hu, Yi ;
Huang, Cheng ;
Zhou, Caicun ;
Shi, Yuankai ;
Han, Jiefei ;
Wang, Di ;
Tian, Yanhua ;
Yang, Zhenlin ;
Zhang, Li ;
Chuai, Shaokun ;
Ye, Junyi ;
Zhu, Guanshan ;
Zhao, Junhui ;
Wu, Yi-Long ;
Wang, Jie .
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (12) :1857-1870
[9]   Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation [J].
Fukuhara, Tatsuro ;
Maemondo, Makoto ;
Inoue, Akira ;
Kobayashi, Kunihiko ;
Sugawara, Shunichi ;
Oizumi, Satoshi ;
Isobe, Hiroshi ;
Gemma, Akihiko ;
Harada, Masao ;
Yoshizawa, Hirohisa ;
Kinoshita, Ichiro ;
Fujita, Yuka ;
Saijo, Yasuo ;
Hagiwara, Koichi ;
Morita, Satoshi ;
Nukiwa, Toshihiro .
LUNG CANCER, 2015, 88 (02) :181-186
[10]   Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC [J].
Hellyer, Jessica A. ;
Padda, Sukhmani K. ;
Diehn, Maximilian ;
Wakelee, Heather A. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :395-403